Rolling review of medical insurance, the formation of an innovative national team... It is recommended that multiple initiatives be taken to promote pharmaceutical innovation

Rolling applications for enterprises, rolling review of medical insurance, and real-time update of catalogs; it is recommended to form a "national team" for pharmaceutical industry innovation; attach importance to the use of innovative drugs in the reform of medical insurance payment methods; accelerate the digital transformation of the pharmaceutical industry... At this year's two sessions, the People's Daily health client combed and found that many representatives of the pharmaceutical industry suggested multiple measures to promote pharmaceutical innovation.

Zhao Chao, deputy to the National People's Congress and chairman of Buchang Pharmaceutical:

Enterprise rolling application, medical insurance rolling review, real-time directory update

The speed of new drugs, especially "life-saving drugs", has accelerated significantly, but in terms of new drug research and development transformation and patient accessibility, some problems need to be broken through urgently, and the incentive and guidance of medical insurance for pharmaceutical innovation is insufficient, and the current medical insurance collection promotes a significant price reduction of drugs, but it is necessary to consider the research and development enthusiasm of innovative pharmaceutical companies in the long run.

For innovative drugs, it is recommended to fully consider the different life cycles of drugs, give certain price reduction protection to protect the enthusiasm for innovation, and explore the transformation of drug access from the "invitation system" to the "declaration system" to accelerate the entry of innovative drugs into medical insurance. After the new drug is listed, enterprises can apply for medical insurance without waiting for the medical insurance negotiation time window, so as to achieve "rolling application of enterprises, rolling review of medical insurance, and updating of the catalog from time to time", so that patients can use new drugs with significant clinical value as soon as possible.

Sun Piaoyang, deputy to the National People's Congress and chairman of Hengrui Pharmaceutical:

It is recommended to expand the effect of compensation for the patent term of drugs

In June 2021, the newly revised Patent Law of the People's Republic of China came into effect, which clarified the establishment of a compensation system for the term of drug patents. However, according to the current implementation rules and examination guidelines for soliciting comments, the effect of compensation for this period is too narrow, resulting in innovative drugs having the opportunity to obtain compensation for the term of patents, but their effect of preventing generic drugs or improved new drugs may be reduced.

It is proposed that during the revision of the Detailed Rules for the Implementation of the Patent Law and the Patent Examination Guidelines, it is recommended that imported new drugs that have undergone complete clinical trials in China be allowed to receive patent term compensation.

In addition, it is recommended to enhance the effect of patent term compensation, at least for innovative drugs on the market for the first time, when using a compound patent to apply for term compensation, its term compensation effect should be able to cover all indications of the drug, not limited to the indications approved at the time of application.

Li Yan, deputy to the National People's Congress and president of Qilu Pharmaceutical Group:

Proposed to form a "national team" for pharmaceutical industry innovation

The number of new drugs applying for clinical trials every year has increased significantly, the number of innovative drugs listed has reached a record high, and the ability of enterprises to carry out international cooperation has been continuously enhanced; but it is undeniable that the concentration of the mainland pharmaceutical manufacturing industry is still low, the task of upgrading the product structure is urgent, and the innovation ability, especially the original innovation ability, is insufficient.

The first suggestion is to do a good job in strengthening the planning of the pharmaceutical industry, and it is recommended to set up a national drug policy committee (or a joint ministerial meeting). Coordinate the formulation and introduction of drug policies, review and control, and ensure the organic unity between relevant policies of various departments.

The second is to form a pharmaceutical industry innovation "national team", establish relevant mechanisms, introduce relevant support policies, concentrate the strength and resources of domestic drug innovation advantage enterprises, and help promote and promote China's drug innovation and research and development in different main directions.

The third is to support the innovative development of key backbone pharmaceutical enterprises, focus on "supporting the excellent and supporting the strong", cultivate several large enterprises with rapid development as support, especially for outstanding national pharmaceutical enterprises with strong industrial foundation, broad development prospects, self-discipline, great potential, and cultivatable, resource tilt and policy support.

Ding Lieming, deputy to the National People's Congress and chairman of Beida Pharmaceutical

In the reform of medical insurance payment methods, we should attach importance to the use of innovative drugs

From the perspective of encouraging innovation and protecting innovation, the payment method of innovative drugs has been further improved: the implementation of a separate payment policy for innovative drugs, especially for national drugs; and the mechanism for giving priority to the use of national collection of winning drugs.

In February 2019, the National Medical Insurance Bureau issued the "Opinions on the Centralized Procurement and Use of Pilot Medical Insurance Supporting Measures for National Organizations", proposing that "all pilot areas should combine to promote the reform of medical insurance payment methods, improve the incentive and constraint mechanism and risk sharing mechanism of 'balance retention, reasonable sharing of overexpenditure', and encourage medical institutions to use selected drugs".

It is necessary to continue to effectively increase policy guidance and implementation efforts, further clarify specific provisions that are operable, focus on improving the priority and proportion of use of the national collection of winning drugs, set only a lower limit and no upper limit on the proportion of use, cancel the requirements of cost control and drug proportion, ensure that medical institutions give priority to the use of winning drugs, and improve the performance appraisal guidance and incentive and constraint mechanism, so as to achieve a benign linkage between DRG/DIP payment, medical insurance negotiation, and drug procurement.

Chen Baohua, deputy to the National People's Congress and president of Zhejiang Huahai Pharmaceutical:

The national collection and mining has entered a critical period, and it is recommended to accelerate the expansion of collection and mining

At present, the national collection has entered a critical period. In the implementation of the original policy provisions, vertical promotion and horizontal field matching, there are still some problems that need to be solved urgently: First, the similar drugs of the selected drugs have not yet been collected, affecting the use of the selected drugs. Second, the selected drugs are not included in the National Essential Drugs List, which restricts the use of grass-roots drugs. Third, it is difficult for selected drugs to be sold in pharmacies.

The first recommendation is to include the selected drugs in the collection and collection into the national essential drugs list as soon as possible, and promote the use of the selected varieties, especially chronic disease drugs, at the grass-roots level. Second, we must use big data and other means to increase the collection and reporting volume of medical institutions; third, we must plug the loopholes in the use of high-priced drugs through collection coverage or the implementation of price limits. Accelerate the collection and collection of similar drugs (including generic drugs and original research drugs that have passed the patent protection period) of public medical institutions; fourth, we must accelerate the expansion of national collection and collection.

Yu Qingming, deputy to the National People's Congress, secretary of the Party Committee and chairman of the board of directors of Sinopharm Group Sinopharm Holdings

It is recommended that multiple departments jointly formulate incentive policies to accelerate the digital transformation of the pharmaceutical industry

With the promotion of policies such as the two-invoice system and collection, the development of new technologies and big data, the pharmaceutical supply chain service field needs to meet many requirements such as safety, timeliness, accuracy, transparency, coordination and efficiency, and the pharmaceutical circulation network needs to develop to flattening, multi-warehouse integration and intelligence.

It is recommended that multiple departments jointly formulate incentive policies to promote the digital transformation and application innovation of the pharmaceutical industry; vigorously support the coordinated development of telemedicine, mobile diagnosis and treatment, digital hospitals, digital logistics, etc.; open up the all-digital business link of the pharmaceutical industry from upstream manufacturers to downstream customers, build a digital system of multi-level control and control, realize penetrating supervision, and help the industry reduce costs and increase efficiency, and improve the quality of development.